Nuvation Bio rises on FDA label update for Ibtrozi
Grandbrothers/iStock Editorial via Getty Images
Nuvation Bio (NUVB) traded higher in the premarket on Thursday after the FDA approved a supplemental New Drug Application, clearing a label update for its cancer therapy Ibtrozi to include new mid-stage trial data.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.